Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATE ESUS: Rivaroxaban vs Aspirin for Secondary Stroke Prevention
NCT02313909Phase 3Terminated
- Sponsor
- Bayer
- Start
- Dec 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of rivaroxaban in embolic stroke of undetermined source (ESUS), sponsored by Bayer. Started Dec 2014; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
embolic stroke of undetermined source (ESUS)
Beyond the preview
Go deeper on NCT02313909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313909.